ArticleFuture oncology (London, England)2024

TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer.

Rayan Kabirian et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.